BOSTON, June 27, 2012 /CNW/ - EvaluatePharma®, the premier source for pharmaceutical and biotechnology sector
analysis and consensus forecasts, has named Debbie Paul to the position
of CEO Americas, EvaluatePharma USA, Inc. effective immediately. In
her new role, Paul leads EvaluatePharma's growing North American
operations and its strategic expansion into Canada and Latin America.
Debbie Paul has been a key member of the EvaluatePharma executive team
since 2004, most recently serving as Senior Vice President, North
America. She brings knowledge gained through more than 25 years of
truly diverse healthcare and life science industry experience, ranging
from being a critical-care nurse manager to directing market research
for a global pharmaceutical company.
Jonathan de Pass remains as chief executive of the U.K.-based parent
company, EvaluatePharma Ltd. Dr. de Pass founded EvaluatePharma in
1996, leading the way in creating new industry standards for consensus
forecasting global drug sales and other performance metrics for the
pharmaceutical and biotech sectors, as exemplified in two recent
industry reports: "World Preview 2018: Embracing the Patent Cliff" and "Surveying Tomorrow's Biopharma Landscape: The NASDAQ Biotech Index Up
Close." Dr. de Pass has since expanded EvaluatePharma into the United States
and Japan markets, serving a growing demand for the company's data
"Debbie has clearly demonstrated her strategic leadership in growing and
serving EvaluatePharma's expanding client base in the Americas," said
Dr. de Pass. "Her experience and comprehensive understanding of the
pharmaceutical and biotechnology marketplace, as well as the healthcare
industry at large, gives her a talent for delivering actionable
knowledge to all of the sector's participants, big and small. She
stands out as the leader with the expertise to continue our growth
during such a pivotal time for pharmaceutical and biotechnology
industries in the Americas."
Prior to joining EvaluatePharma, Debbie Paul served as Director of
Market Research at Sandoz, the generics division of global
pharmaceuticals company Novartis AG, where her focus was strategic and
product planning. She also worked in the pharmaceutical and medical
products practice of management consultancy McKinsey & Co., Inc. Paul
received her Masters of Business Administration from Rice University in
Houston, Texas, following a 17-year career as a critical care nurse.
She also holds a Bachelor of Science in Nursing from State University
of New York in Albany.
Since 1996, EvaluatePharma has been the premier source for
pharmaceutical and biotechnology sector analysis, delivering exclusive,
trusted commercial insight into industry performance through its
proprietary platform. EvaluatePharma is staffed by a team of 75
dedicated healthcare analysts employing rigorous methodologies to
collate, organize and deliver the most-up-to-date commercial
performance data available. An award winning editorial team of
journalists writing under the EP Vantage name support EvaluatePharma's analysis. The EvaluatePharma® services enable the life science community to make sound business
decisions about value and opportunity. For the complimentary industry
reports mentioned above and more information please visit http://www.evaluatepharma.com.
SOURCE EvaluatePharma USA, Inc
For further information: